Clinical trial
Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving…
NCT00358540 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00358540 |
|---|---|
| Title | Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide |
| Official title | An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Thrombocytopaenia |
| Intervention type | Drug |
| Interventions | eltrombopag |
| Enrollment | 18 |
| Start date | Jun 1, 2006 |
| Primary completion | Oct 22, 2010 |
| Completion | Oct 22, 2010 |
| First posted | Aug 1, 2006 |
| Last update posted | Nov 13, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: